一本关于新药发现与研发的英文书。Charles G. Smith Ph.D.James T. O’Donnell Pharm.D.
Repositioning existing drugs for new indications can offer a better risk-versus-reward trade-off as compared with other drug development strategies, and can help to deliver the productivity increases the industry needs while shifting the locus of production to biotechnology companies. Representative repo...
Development Phase Phase 1 Phase 2 Phase 3 Registration Area Of Focus Inflammation & Immunology Internal Medicine Oncology Vaccines Submission Type New Molecular Entity Product Enhancement Compound Type Biologic Small Molecule Vaccine Project Status Current Discontinued Project Adv...
Initiatives to speed new drug development and regulatory review: the im- pact of FDA-sponsor conferences. Drug Inf J. 1997;31(3):771-788.DiMasi JA, Manocchia M (1977) Initiatives to speed new drug development and regulatory review: the impact of FDA-sponsor conferences. Drug Info J 31:...
(1997) Is there a need to improve contemporary drug development? Presentation given at the 33rd Annual Meeting of the Drug Information Association, Montreal, Quebec, Canada, June 23. Google Scholar U.S. Food and Drug Administration, Washington, DC. Website: http://www.fda.gov. Public ...
Epilepsy is a common brain disorder, characterized by spontaneous recurrent seizures, with associated neuropsychiatric and cognitive comorbidities and increased mortality. Although people at risk can often be identified, interventions to prevent the deve
We also identified promising compounds in preliminary phases of drug development including inhibitors of survivin, antiapoptotic Bcl-2 family proteins, methyltransferase, and kinesin proteins. This systematic approach may be applied more broadly to prioritize drugs to be repurposed or to identify novel ...
New Learnings: Advancing Drug Discovery and Development through Non-Invasive Biodistribution ImagingNew Learnings: Advancing Drug Discovery and Development through Non-Invasive Biodistribution ImagingCopyright (c) 2013 Molecular Imaging, Inc. All rights reserved. This material may not be reproduced,...
research and development agreement with Quadrant to develop an extended-release formulation of iloprost inhalation solution. Iloprost was designated as an orphan medicinal product for the treatment of pulmonary hypertension in December 2000 by the EMEA and will fall under orphan drug protection until ...
Development Phase Phase 1 Phase 2 Phase 3 Registration Area Of Focus Inflammation & Immunology Internal Medicine Oncology Vaccines Submission Type New Molecular Entity Product Enhancement Compound Type Biologic Small Molecule Vaccine Project Status Current Discontinued Project Adv...